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Background: In response to calls to expand the scope of research ethics to address justice in global health, recent
scholarship has sought to clarify how external research actors from high-income countries might discharge their
obligation to reduce health disparities between and within countries. An ethical framework—‘research for health
justice’—was derived from a theory of justice (the health capability paradigm) and specifies how international clinical
research might contribute to improved health and research capacity in host communities. This paper examines
whether and how external funders, sponsors, and researchers can fulfill their obligations under the framework.
Methods: Case study research was undertaken on the Shoklo Malaria Research Unit’s (SMRU) vivax malaria treatment
trial, which was performed on the Thai-Myanmar border with Karen and Myanmar refugees and migrants. We
conducted nineteen in-depth interviews with trial stakeholders, including investigators, trial participants,
community advisory board members, and funder representatives; directly observed at trial sites over a five-week
period; and collected trial-related documents for analysis.
Results: The vivax malaria treatment trial drew attention to contextual features that, when present, rendered the
‘research for health justice’ framework’s guidance partially incomplete. These insights allowed us to extend the
framework to consider external research actors’ obligations to stateless populations. Data analysis then showed
that framework requirements are largely fulfilled in relation to the vivax malaria treatment trial by Wellcome Trust
(funder), Oxford University (sponsor), and investigators. At the same time, this study demonstrates that it may be
difficult for long-term collaborations to shift the focus of their research agendas in accordance with the changing
burden of illness in their host communities and to build the independent research capacity of host populations
when working with refugees and migrants. Obstructive factors included the research funding environment and
staff turnover due to resettlement or migration.
Conclusions: Our findings show that obligations for selecting research targets, research capacity strengthening,
and post-trial benefits that link clinical trials to justice in global health can be upheld by external research actors
from high-income countries when working with stateless populations in LMICs. However, meeting certain
framework requirements for long-term collaborations may not be entirely feasible.
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International clinical research (ICR) is increasingly being
performed in low- and middle-income countries (LMICs),
where stark inequalities in health and health research
systems may be observed. In recognition of the growing
global context of research and lack of benefits accruing
to LMICs, Benatar and Singer argued that research ethics
should address the linkages between international research
and justice in global health [1]. It should serve to connect
the enterprise to improvements in health and research cap-
acity in host communities. This call to expand the scope of
research ethics has been reiterated by others [2-4].
Scholarship is developing a “broader bioethics agenda
of equity and population health” [5] by considering what,
if anything, parties from high-income countries owe to
parties in LMICs to reduce health disparities between and
within countries, and what this means for the conduct of
international research [6-10]. Theories of justice drawn
from political philosophy provide grounds to establish ob-
ligations for actors in rich countries to improve the health
of populations in poor countries [11,12]. An ethical frame-
work—the ‘research for health justice’ framework—de-
rived from the health capability paradigm specifies how
external research actors from high-income countries
might discharge their obligation [8]. The health capability
paradigm is a theory of justice that extends the work of
Sen and Nussbaum and specifically addresses health
[11,13]. It was selected as the basis of the ethical frame-
work because it has primary and subsidiary principles that:
1) require the conduct of health research and research
capacity strengthening and 2) can establish specific obliga-
tions for external research actors from high-income coun-
tries to trial participants and host communities [14].
‘Research for health justice’ describes how three aspects
of ICR—selection of the research target, research capacity
strengthening, and post-trial benefits—should be orga-
nized for the enterprise to advance the ends of global
justice. The framework recognizes that actors beyond
researchers (i.e., governments, research funders, and
sponsors) have obligations of justice and that the fulfill-
ment of their obligations is necessary for researchers to
satisfy their obligations. Its requirements differ from the
justice requirements articulated in international research
ethics guidelines such as responsiveness and reasonable
availability [8]. This reflects the fact that the framework
and international guidelines are intended to address differ-
ent objectives—namely, justice at the macro-level (reduction
of global health inequities) and justice at the micro-level
(distributive justice in the context of single trials). Linking
international research to global justice entails different
ethical requirements than achieving a fair balance of
benefits and burdens in individual trials does.
‘Research for health justice’ requires that ICR be under-
taken in communities whose health status is far from theoptimal global level. The responsiveness requirement,
however, places no restrictions on the selection of host
communities [8]. It allows international research to be
performed in high-income countries or with populations
that have decent health in LMICs. Under ‘research for
health justice’, ICR must address health conditions that are
major contributors to the poor health status of worst-offa
communities in LMICs. It is not sufficient for the
condition-under-study simply to be prevalent or repre-
sented in the host community (i.e., to be a health need),
which is permitted by international guidelines, including
the Declaration of Helsinki and the CIOMS guidelines [8].
Resultant interventions must be culturally appropriate and
likely to be made available to host communities post-trial.
ICR should also be conducted as part of a long-term
collaboration with local researchers and institutions.
Over time, these collaborations’ disease focus should
shift to reflect any changes in the disease burden of their
host communities. They should build local researchers
and institutions’ capacity to independently conduct clinical
research on health conditions that are primarily respon-
sible for their population’s poor health status. International
guidelines neither require researchers and sponsors to en-
gage in (long-term) collaborations nor offer guidance on
the nature of the disease focus of these collaborations’ re-
search. They largely do not clarify the nature of research
capacity to be strengthened or call for building capacity
beyond the duration of a single trial [8].
‘Research for health justice’ requires that post-trial ac-
cess to efficacious interventions be supported in host
communities by a global health institution and, wher-
ever possible, be delivered by state health systems [8].
Obligations are allocated according to the health cap-
ability paradigm’s functional requirements principle, so
parties are assigned obligations because the functions
they typically assume make them particularly capable of
fulfilling the obligations [11]. As a result, in contrast to
international guidelines, researchers and sponsors are
not given the primary obligation to provide interven-
tions proven efficacious post-trialb. That responsibility
is allocated to global health institutions that work to-
wards creating access to medicines [8]. (A more compre-
hensive summary of framework requirements is provided
in Additional file 1 and Additional file 2.)
Although research actors’ obligations of global justice
are starting to be defined, practices capable of fulfilling
them have not been described. As has been noted,
[c]urrently, little information is available to ascertain
what types of research are actually being undertaken
in developing countries, how much work is being done,
the benefits that studies presently offer communities,
and whether research addresses the needs of
developing countries, developed countries, or both [15].
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quirements relating to justice irrespective of how it is con-
ceived (i.e., at the micro or macro-level). In 2001, a study
exploring the extent to which international research ethics
guidelines were observed solicited researchers’ perspec-
tives on their projects’ responsiveness to local needs,
standard of care for participants, provision of study inter-
ventions post-trial, and capacity-building [16]. More re-
cently, the Global Campaign for Microbicides conducted
a study assessing the standard of care achieved in six
African microbicide trials [17]. These studies did not
investigate how ethical requirements relating to justice
at the micro-level were fulfilled. Yet that information is
essential to translating ethical guidance into practice.
Fulfilling justice requirements in resource-poor settings
is complex and empirical research can provide critical
information for research actors [18].
This paper explores how ethical obligations connecting
international research to justice in global health can be
achieved when conducting research with stateless popu-
lationsc. To test whether and how ‘research for health
justice’ can be upheld, we undertook case study research
with the Shoklo Malaria Research Unit (SMRU). Its on-
going vivax malaria treatment (VHX) trial was examined
for consistency with framework requirements. Data col-
lected through in-depth interviews with trial stake-
holders, direct observation at trial sites, and examination
of trial-related documents were analyzed according to
the principles of thematic analysis. During this analysis,
shortcomings of the framework were identified, as the
VHX trial drew attention to contextual features that,
when present, rendered its guidance incomplete. Insights
from this case study allowed us to extend ‘research for
health justice’ in ways not previously contemplated.
Once gaps in the framework were addressed, we were
able to complete our assessment of the VHX trial. Even
though this was a retrospective application of a new fra-
meworkd, we found that Wellcome Trust (funder), Oxford
University (sponsor), and trial investigators upheld most
of their obligations. We describe the facilitating and ob-
structive factors. Where stakeholders did not uphold obli-
gations, plausible reforms to practice are suggested.
Some of the data generated by our empirical research
on SMRU are mentioned in an earlier methods paper [18].
They were included at the request of reviewers in order to
demonstrate the outputs of our research method. In this
paper, the data are analyzed using ‘research for health just-
ice’ as the normative framework because the aim of our
case study research was to investigate whether and how
SMRU’s VHX trial was able to promote global health just-
ice. We, therefore, assessed the practices of the VHX trial’s
funders, sponsors, and researchers for alignment with a
framework that describes how ICR can advance such ends
(rather than with ethical requirements designed to promotejustice at the micro-level). (The methods paper briefly
evaluates researchers’ adherence to international guide-
lines’ requirements for responsiveness, research capacity
strengthening, and reasonable availability.)
Methods
Case study methodology was used in this study because
it enables exploration of how and why a complex social
phenomena works and can bring out important context-
ual features [19]. We describe the case under study, the
specific methods used to collect data on it, and the role
of SMRU co-authors in the study below.
The case under study
We selected SMRU and its VHX trial as our case study
because, for the past 25 years, SMRU has been consciously
designing its clinical trials to meet the health needs of its
host community. It was, therefore, more likely that an
SMRU trial would demonstrate whether ‘research for
health justice’ requirements could be upheld than many
other clinical studies and provide data on how this was
achieved.
SMRU is a field research site of the Mahidol-Oxford
Tropical Medicine Research Unit located in Mae Sot,
Thailand. It has been conducting operational research
since 1985 with Karen and Myanmar refugees, migrants,
and displaced persons living on the Thai-Myanmar
border. The Karen, one of the largest ethnic groups in
Myanmar and northern Thailand, has been engaged in
armed rebellion against the Myanmar military forces since
1949. This conflict has forced hundreds of thousands of
refugees to flee to Thailand. Economic stagnation in
Myanmar has also led millions of migrant workers to set-
tle in the border region and seek work in Thailand. As
such, the border population is not homogenous. Refugees
are primarily Karen and physically situated in Thailand in
camps like Mae La. They may stay in these camps for a
few months to decades. The Thai government considers
these refugees to be under its authority [20]. Migrants live
on either side of the border. Those in Myanmar may rou-
tinely cross into Thailand for work or to access health care
at an SMRU clinic. Migrants are more mobile than the
refugees based in camps. Some of those entering Thailand
for work are registered migrants with work permits. In
2004, there were 610,106 registered migrants and 1.3 mil-
lion illegal migrants [20]. A proportion of the border
population are effectively permanent residents of Thailand
while others regularly cross the bordere.
Although Thai and Myanmar hospitals are in the vicin-
ity of the border, they are physically and financially diffi-
cult for refugees, illegal migrants, and displaced persons
to access. Reaching a Thai hospital requires travelling at
least 15–20 kilometers beyond the border and/or passing
through military checkpoints intended to prevent Myanmar
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nor Thailand make their health systems accessible to the
border population, over the past fifteen years, SMRU has
established free clinics to fill the health care gap. It is both
a research unit and health care provider. SMRU’s research
profile includes falciparum and vivax malaria, respiratory
diseases, malaria in pregnancy, and child health. There
may be five to ten ongoing clinical trials at any time.
The VHX trial is funded as part of a Wellcome Trust
Programme Grant. It seeks to describe the epidemiology
and compare the efficacy of three treatments for vivax
malaria—chloroquine/primaquine, chloroquine, and arte-
sunate (web reference: http://clinicaltrials.gov/ct2/show/
NCT01074905). Trial sites are five SMRU clinics—Mae
La, Wang Pha, Mawker Thai, Mun Ru Chai, and Mae Kon
Ken—and there were roughly 410 VHX trial participants
at the time of our research. Of the five clinics, only Mae
La Clinic is located in a refugee camp. The four remaining
clinics primarily service Myanmar migrants and are lo-
cated just over the Thai side of the border. Myanmar na-
tionals do not need to cross a Thai military checkpoint to
reach these clinics. However, habitual flare-ups of violence
along the border can present a barrier to accessing SMRU
clinics. As SMRU has been operating for over 25 years,
the VHX trial is performed as part of a longstanding re-
search collaboration.
Case study methods
Data on the VHX trial were collected using a triangulation
approach that relied on in-depth interviews, direct obser-
vation, and document analysis. Nineteen semi-structured
in-depth interviews were conducted with four types of
VHX trial stakeholders—investigators (five interviews),
Tak Province Border Community Ethics Advisory Board
(T-CAB) members (four interviews), trial participants
(eight interviews), and Wellcome Trust science portfolio
advisors (two interviews). A series of open-ended ques-
tions was designed such that interviewees were asked to
describe, first, their roles and responsibilities during each
stage of the VHX trial and, second, their perspective on
the health impact of the trial on participants and the
border population [18]. For interviews with trial partici-
pants and T-CAB members, a translator was used. Inter-
views were an average duration of 72 minutes [18].
Interview data were supplemented by direct observation
at four of the five VHX trial sites over a five-week period
in March and April 2011 and by an examination of trial-
related documents. To collect data, BP travelled to SMRU
clinics nearly every weekday over a five-week period. The
main observation strategy was to try and identify VHX
trial participants based on the medical tests they received,
to confirm this with SMRU medics, and then to continue
observing those individuals to determine what trial-related
and ancillary care they received. BP also observed theresearch skills of the Karen clinic staff [18]. Participant re-
cruitment and data collection methods are comprehen-
sively described in Pratt et al. (2012) [18]. Ethical approval
for the study was obtained from the Ethics Committee of
the Faculty of Tropical Medicine at Mahidol University,
the Tropical Research Ethics Committee at Oxford
University, and the Monash University Human Research
Ethics Committee.
Written consent was obtained from all interviewees by
either BP, KML (with BP also present), or a translator
(with BP also present). Prospective interviewees were
provided with both a Participant Information Sheet and
Consent Form in English or Burmese. Prior to signing
the Consent Form, interviewees had the research project
explained to them, read the Participant Information
Sheet and Consent Form (or had the forms read to them
if they could not read), and were given time to consider
entering the study and to ask questions. The Participant
Information Sheet and Consent Form used for the case
study research detailed the aims, methods, anticipated
benefits and risks of the research, data storage procedures,
study investigator contact information, and complaints
procedure. These documents informed prospective inter-
viewees that taking part in the study was voluntary, that
they could choose not to participate in the study, and that
they could withdraw at any stage of the study, without giv-
ing a reason. Prospective interviewees were also informed
that their names and responses would not be shared with
anyone outside the study team, that the information they
gave during interviews would be de-identified, and that
their names would not be used in any reports or publica-
tions based on the study.
Participants who chose to take part in the study and
who could read and write signed two copies of the Con-
sent Form, one for their records and one for the study
team’s records. (They were given a copy of the Partici-
pant Information Sheet to keep as well.) Participants
who were not literate were also asked to sign two copies
of the Consent Form. This was because, despite not be-
ing able to read or write, illiterate individuals were able
to sign their name and it was considered insulting to ask
them to provide a thumbprint instead of a signature. In
such cases, the person who took their consent signed
each copy of the Consent Form, affirming that s/he
“hereby testifies that the content of this letter of consent
and the explanation about the study were read to the
participant. The participant had the opportunity to ask
questions about it and any questions that have been asked
have been answered to his/her satisfaction. He/she is
pleased to willingly participate in this study voluntarily.”
Interviews were transcribed verbatim and translated
from Burmese to English where required. To ensure the
accuracy of translation, two interviews were re-translated
by a co-investigator who is fluent in Burmese and English.
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translation and that of our transcriber. Data were ana-
lyzed according to the principles of thematic analysis
described in Braun and Clarke [21], with co-coding per-
formed independently by two researchers. Once themes
were identified that pertained to the selection of the re-
search target, research capacity-building, and post-trial
benefits, we assessed whether their collated data ex-
tracts provided evidence that the VHX trial met ‘re-
search for health justice’ framework requirements. The
results of that analysis are subsequently discussed, fol-
lowing clarification of the framework’s guidance on obli-
gations to stateless populations and post-trial benefits in
operational clinical research.
Role of SMRU authors
Three of the authors of this paper are employed by
SMRU. In this section, we describe who they are and
their role in the data collection phase of this research
study. We consider how their role in collecting data
might have affected what data was generated and
whether their involvement might limit the objectivity of
this study.
KML is a physician-investigator from Myanmar who
has worked at SMRU for over five years and is based in
Mae Sot. PYC is the Head of the Clinical Trials Support
Group in the Mahidol-Oxford Tropical Medicine
Research Unit. She is primarily based in Bangkok but
travels regularly to Mae Sot. FN has been the director of
SMRU since its inception in 1985 and is based in Mae
Sot.
These authors were involved in the development of
the interview question guides for T-CAB members and
trial participants. This ensured that the questions were
relevant to the nature of T-CAB members and trial par-
ticipants’ involvement in the VHX trial and would be
understood by such individuals. In March 2011, BP con-
sulted with FN, KML, PYC, and a VHX trial investigator
regarding the content of the interview guides. Changes
were made to the T-CAB member and trial participant
interview guides as a result. The aforementioned individ-
uals advised that trial participants and T-CAB members
would be better able to respond to targeted rather than
open-ended questions. In order to elicit as much narra-
tive as possible and to avoid getting only yes or no an-
swers, BP added the phrases “Why” or “Please provide
an example” to the end of certain questions. These indi-
viduals also noted that asking participants about what
will happen when the VHX trial is over (i.e. in the fu-
ture) might not be well understood or easily translated
into the Burmese language. They recommended that the
term “malaria” rather than vivax be used because trial
participants would not know that there are different
forms of malaria. Together, the VHX trial investigator,KML, and BP re-wrote the trial participant interview
guide, maintaining the integrity of its content while alter-
ing some of its wording. BP then re-wrote the T-CAB
interview guide and KML approved the new version.
Based on a clear criterion, FN, PYC, and KML also
assisted in the identification of suitable T-CAB members
to interview. Five of fourteen T-CAB members were se-
lected because they lived in the villages near the VHX
trial sites and would, therefore, be best able to describe
the impact of the trial on its host communities. Four of
those T-CAB members were available and consented to
be interviewed. The fifth T-CAB member was in Myanmar
at the time of this study and was not able to be contacted
for interview.
KML was responsible for recruiting and interviewing
T-CAB members in Burmese. During these interviews,
BP was present and KML repeated interviewees’ responses
in English to her after they answered each question in the
interview guide. T-CAB members have an ongoing rela-
tionship with KML. KML and PYC facilitated the estab-
lishment of the SMRU T-CAB and act as its coordinators,
facilitating monthly meetings where SMRU investigators
present on upcoming clinical research projects. Although
KML and PYC attend and facilitate each T-CAB meeting,
they do not participate in T-CAB members’ deliberations.
Even so, T-CAB members may perceive them to be au-
thority figures. Perhaps this impacted their decision to
consent to be interviewed as part of this study, but we
would emphasise that T-CAB members were not pres-
sured to participate. Their recruitment proceeded in an
ethical manner and they understood that their decision
to participate had no implications for their involvement
in T-CAB or their future treatment. (T-CAB member-
ship is voluntary, with members receiving compensation
for their time and transportation costs. Members also
report benefits for themselves through their involve-
ment such as enhanced knowledge and roles as educa-
tors in their communitiesf ).
As part of the interviews with T-CAB members, KML
asked questions to determine what the health concerns
were in their communities and whether vivax malaria
was one of them. He also asked T-CAB members to
describe how SMRU research improves health in their
communities during and after trials and how SMRU
research benefits their communities. These questions
were pertinent to assessing whether the VHX trial was
consistent with ‘research for health justice’ requirements
for selecting research targets and post-study benefits.
We acknowledge that having KML conduct these inter-
views had potential to affect interviewees’ responses,
perhaps generating an overly favourable response about
the impact of SMRU and/or an agreement that vivax
was a major health concern. T-CAB members stated that
once SMRU research indicates that new treatments are
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SMRU doctors will revise their practices and use the
new medicines. This does not appear to be an exagger-
ated assessment of SMRU’s impact. It is consistent with
comments made by VHX trial investigators in their in-
terviews and with SMRU’s practices relating to its previ-
ous research on falciparum malaria treatment. T-CAB
members understand the difference between vivax and fal-
ciparum and were actually more likely to cite falciparum
as a concern than vivax. They were also willing and able
to identify non-malarial health concerns when asked.
Finally, KML was responsible for re-translating two T-
CAB interview transcripts in order for a comparison to
be made with the translation of the same transcripts by
our Melbourne-based transcriber. This was done to as-
sess the accuracy of the transcription done by our tran-
scriber. There were no significant differences between
KML’s translation and that of our transcriber.
KML, PYC, and FN were not involved in any of the
other interviews with VHX trial participants, investiga-
tors, or funder representatives. They were also not in-
volved in the direct observation aspects of the study. We
believe that the nature of the involvement of these three
authors was not of a kind to raise concerns about the
validity of study findings.
Extending the ‘research for health justice’
framework
The ‘research for health justice’ framework made two as-
sumptions about ICR that were not reflected in the VHX
trial: 1) all individuals are citizens of a state and 2) ICR
is directed towards evaluating new health interventions.
The Karen and Myanmar border population is essen-
tially stateless and the VHX trial aims to optimize an
existing treatment for vivax malaria. To apply the frame-
work to the VHX trial, it was necessary to develop guid-
ance on what is owed to stateless populations and the
content of post-trial benefits in operational clinical re-
search. Extending the framework did not force a devi-
ation from health capability paradigm principles.
Obligations to stateless research populations
The ‘research for health justice’ framework did not iden-
tify who external institutions and researchers should
work with when trial participants are stateless. Are ex-
ternal VHX trial stakeholders expected to work with re-
search institutions and researchers in Myanmar to build
their clinical research capacity and rely on the Myanmar
health system to create post-trial access to study inter-
ventions? Or are they required to work with Thai re-
search institutions and researchers and rely on the Thai
health system?
The fact that individuals have fled Myanmar does not
absolve the state of responsibility for fostering theirhealth capabilities. Under the health capability paradigm,
states have the primary obligation to ensure their popu-
lations’ freedom to be healthy. Where states are unable
or unwilling to provide their populations’ health entitle-
ments, the paradigm obliges global actors to help states
meet their obligations. Myanmar has an obligation to
reform its regime such that it is better able to meet
the (health) needs of its ethnic minorities. Nonetheless,
when citizens of a state seek refuge in another state, we
take the position that the state of refuge assumes second-
ary responsibility for achieving just health outcomes for
those individuals, provided it is capable. Global actors and
institutions have an obligation to assist the state of refuge
to promote the health capabilities of the stateless popula-
tion. Accordingly, external research actors have an obliga-
tion to build research capacity at the institutional level
in the state of refuge and at the individual level in the
state of refuge and among the migrant and refugee
populationsg.
In allocating obligations of justice to the state of refuge,
the framework assumes that states that are able to meet
their obligations to refugees will do so. In this instance,
the assumption is that Thailand will take responsibility for
the stateless populations within its borders, giving global
actors clear partners with whom to work. Again, however,
the context of the VHX trial is inconsistent with frame-
work assumptions. Thailand’s health system is generally
inaccessible to the border population, though health care
is available to some registered migrantsh. Where states do
not uphold their obligations and post-trial access cannot
be coordinated through state health structures, external
actors (including global health institutions), nonetheless,
retain their obligations under the framework.
Post-trial benefits in operational clinical research
The ‘research for health justice’ framework establishes
an obligation to facilitate sustainable access to new inter-
ventions in host communities of phase II, III, and IV clin-
ical trials. Its guidance could not be applied to the VHX
trial because it is operational clinical research designed
to change treatment practice so an existing intervention
is utilized according to a newly optimized regimen. For
operational research, the obligation to provide post-trial
benefits is better articulated as an obligation to change
treatment practice. Changes to practice will ideally be
made accessible to a research population through its
state’s health system.
Results and discussion: Alignment of SMRU’S VHX
trial with ‘research for health justice’
Selection of the research target
For SMRU’s VHX trial to meet the framework’s criteria
for selecting a research target, its host community must
exhibit a large gap in health status from the optimal
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to that gap in health status. A need should exist for clin-
ical research on vivax in the host community and prima-
quine must be appropriate for use by trial participants
and their communities. As a longstanding research col-
laboration, SMRU is also required to demonstrate that
the content of its research agenda has changed in ac-
cordance with any changes that might have taken place
in its host community’s burden of disease over time [8].
Selection of the host community
Francois Nosten came to the Shoklo camp in 1985 to estab-
lish a Médecins Sans Frontières clinic for Karen refugees.
He and Nick White subsequently created SMRU in order
to do clinical research with this population, as there was a
need to improve malaria treatment. Resistance was emer-
ging in Shoklo camp to then-current interventions. Mater-
nal mortality was high, with the estimated maternal
mortality rate at 499 per 100,000 live births [22].
SMRU later expanded its research to migrant workers
and displaced persons outside refugee camps like Shoklo.
In part, this was because malaria transmission dropped in
the camps but remained high in surrounding rural areas.
The estimated maternal mortality rate in the migrant
population was 588 per 100,000 live births in 1996–2000
[22]. By expanding its research population, SMRU dem-
onstrates how a research group can evolve so that it
continues to address the health needs of the worst-off.
Investigator 02 suggests that the choice to expand was
also made because the migrant population was at high-
risk for emerging drug resistance. He states,
they are unprotected population because the
population along the border, most of them, they are
not recognized by any of the country. So they are not
recognized by Thailand and they are not recognized by
Myanmar. They are not under any medical cover for
the health care system of the neighbor countries and
another one is the their migration pattern is very
quick, so that means that the transmission of the
disease pattern is very quick and then the transmission
of the drug resistance is very quick… so we need to
know the treatment we are using is effective and
especially the malaria treatment. We need to know,
are we using the right treatment?
Due to their mobility and poor access to care, migrants
and displaced persons were at high-risk of acquiring
diseases and promoting the emergence of drug resist-
ance to existing treatments. This meant the population
continually required revised treatments for diseases like
malaria.
The selection and expansion of SMRU’s research popu-
lation was consistent with ‘research for health justice’, as itwas based on a combination of the border population’s
poor health and need for clinical research. Today, the
border population has better health than it did in 1985 be-
cause falciparum malaria transmission is much reduced
and access to health care improved once SMRU set up
clinics. Nonetheless, the population remains at high-risk
for infectious diseases and emerging drug resistance. This
contributes to its poor health status, which, according to
Investigator 02, is low when compared to the Thai popula-
tion, whose life expectancy is 73.6 years [23]. The border
population probably has a life expectancy of less than 65
yearsi, though there is no data to verify this. This is a
sizeable gap in health status from the optimal level
(84 years).
SMRU data indicates that the border population’s in-
fant mortality rate is 50 per 1,000 live births. Compara-
tively, the infant mortality rates in Myanmar, Thailand,
and Japan are 47, 15.9, and 2.2 per 1,000 live births re-
spectively [23]j. The maternal mortality rate is estimated
to be 79 per 100,000 live births in the refugee population
and 252 per 100,000 live births in the migrant popula-
tion [22]. (More than 75% of trial participants are from
the migrant population.) The maternal mortality rates in
Myanmar, Thailand, and Japan are 200, 48, and 5 per
100,000 live births respectively [23]k. The border popula-
tion is then an acceptable host community under the
framework, but, as its health continues to improve, SMRU
may need to consider further expanding its research
population.
Selection of the health condition
Vivax is the main cause of malaria in the border popula-
tionl. While falciparum has a greater impact on morbid-
ity and mortality, vivax can cause significant morbidity.
Unlike falciparum, the vivax parasite has liver stages that
can remain dormant for weeks or months. These liver-
stage parasites are not cleared by chloroquine (the
standard of care on the Thai-Myanmar border), so each
vivax infection is associated with multiple relapses [18].
Vivax can cause chronic anemia. In pregnancy, it is the
most common cause of malaria-related anemia and low
birthweight. The disease sometimes results in death. T-
CAB member 04 confirms this, detailing her neighbor’s
experience with the illness:
One of my neighbors, who were able to walk come-
and-go, went to examine malaria virus and found out
that there was none. He even hospitalized once at
Koko Hospital, but wasn’t happy. So, he went to take
the blood out this [SMRU] clinic and found virus and
then found no virus at another time. He’s always sick
and then has become healthy. A moment later, he was
sick again. So, his children came back and took him to
the Mae Tao Hospital. Three or four days later, he
Table 1 T-CAB members and VHX trial participants’ views
on whether malaria is a health concern
Interviewee Identifies malaria
as a health concern*
Reason(s)
T-CAB Member 01 No. Has gained knowledge on
how to prevent malaria.
T-CAB Member 02 Yes. If gets malaria, cannot work.
If gets cerebral malaria, can
die.
T-CAB Member 03 Yes. Thinks people
in his village worry
as well.
If gets malaria, cannot work. “I
cannot eat foods, I will not be
able to do any kind of social
activities and family matter and
then it can effect to all of our
business sector, social sector,
and education sector.” If severe,
malaria virus can cause death.
T-CAB Member 04 Yes. Thinks people
in her village worry
as well.
Large (falciparum) and small
(vivax) malaria virus can
cause death.
Trial Participant 01 Yes. And worries
about malaria
repeating again.
If unhealthy, cannot work.
Trial Participant 02 Yes. Has seen people die
from malaria.
Trial Participant 03 Yes, worries most
about malaria virus.
Scared of “losing my physical
body”.
Trial Participant 04 Yes, worries most
about malaria virus.
Can die if don’t receive
treatment.
Trial Participant 05 Yes, worries for
cerebral malaria.
Can put life in danger.
Trial Participant 06 Yes. Scared of dying, forgetting
things, going crazy, becoming
unconscious.
Trial Participant 07 Yes, worries for
cerebral malaria.
If virus goes to brain, can die.
Trial Participant 08 Yes, worries for
cerebral malaria.
Die if virus goes to the brain.
*Note: T-CAB members are specifically referring to vivax when they say they
are worried about malaria, as they were asked “Do you worry about getting
vivax malaria?”. However, trial participants were asked “Do you worry about
getting malaria?” because they were unlikely to know that there are different
types of malaria. As a result, their answers may refer to falciparum or vivax.
Where trial participants mention cerebral malaria or its symptoms (e.g., trial
participants 05–08), they are expressing a concern for falciparum. Trial participants
02–04 may also be referring to falciparum rather than vivax because falciparum is
more commonly associated with death than vivax. Of the trial participants
interviewed, trial participant 01 is the most likely to be identifying vivax as a
concern, as he mentions relapsing.
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although he looked normal. That’s because the malaria
virus got into liver.
While the incidence of vivax is high and relapses can
result in chronic anemia, it typically does not cause se-
vere illness in adults. Trial investigators do not consider
it to be the top health concern of the border population.
Investigator 01 states that
[v]ivax is a problem but not a serious—I would not
put that as the number one priority in terms of health
in the population. It probably goes after respiratory
infection, diarrheal disease, and in terms of public
health, tuberculosis is emerging as a big problem. Of
course, if you look at just the sheer numbers, of course,
we still treat many more cases of vivax than we treat
tuberculosis, but it’s difficult to compare because one is
a disease that almost you would, you know, could
compare as a flu, as a mild flu, except that in young
children, in very young babies, then it can be
dangerous and in pregnant women it’s not very good,
but in adults it’s like a flu, so you take three tablets of
something and then you are done.
While vivax can have serious consequences for chil-
dren and pregnant women, malaria is no longer the
main cause of severe disease in the border population.
Other infectious diseases are becoming more important
—respiratory illnesses, diarrheal diseases, TB, and, within
the TB population, 20% are HIV positive [18].
Even so, T-CAB members and VHX trial participants
acknowledge that malaria continues to be a concern.
Despite the reduced falciparum burden, many partici-
pants said they are scared of dying from cerebral malaria
(falciparum) during interview [18]. For T-CAB members
and trial participants, common reasons for being wor-
ried about vivax are that the disease will cause death or
affect their capacity to work (see Table 1). T-CAB mem-
bers and trial participants also identified non-malarial
illnesses as being of concern, including cancer, dengue,
and TB (see Table 2).
Although vivax may not be the top health priority
of the border population, it would be inaccurate to
characterize SMRU’s focus on malaria as a deviation
from framework requirements. When SMRU was estab-
lished, falciparum was the main health problem of the
border populationm. Successful implementation of SMRU’s
research results has meant that falciparum is of lesser pri-
ority now. Where the burden of disease in a host commu-
nity changes significantly over time, ‘research for health
justice’ obliges long-term collaborations to modify their
research practice to reflect those changes. SMRU is now
broadening its research agenda to include respiratoryinfections, non-malarial fever-related illnesses (dengue,
leptospirosis, scrub typhus), maternal and child health,
and TB. The decreasing burden of falciparum has led
SMRU to diversify its research agenda. The VHX trial
demonstrates that an immediate shift in research focus
to new health priorities may not be possible.
Thus, the selection of vivax as the condition-under-
study may not meet framework requirements if the
border population’s current burden of disease is consid-
ered alone. When the context of SMRU’s broadening re-
search agenda and history is taken into account, the
Table 2 T-CAB members and trial participants’ non-malarial
health concerns
Interviewee Identified non-malarial health concerns
T-CAB Member 01 Cancer
T-CAB Member 02 TB and cancer. He is as concerned
about these two illnesses as he is
for malaria.
T-CAB Member 03 Diarrhea and dengue
T-CAB Member 04 TB and cancer
Trial participant 01 He is scared of getting diseases
other than malaria and mentions
“diseases of the stomach”, which
may refer to gastroenteritis.
Trial participant 02 She does not worry about other
diseases. “As I have never had it
before, I do not worry about it.”
Trial participant 03 Abdominal disease
Trial participant 05 Dengue and HIV/AIDS
Trial participant 08 He is only scared of sexually
transmitted diseases (and malaria).
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research agenda in accordance with the changing pattern
of disease on the border. Vivax now causes reasonably
substantial morbidity given its relapse rate and inci-
dence. Vivax is enough of a concern to warrant being a
focus of SMRU’s research as it transitions the focus of
its research agenda, provided there is a need for clinical
research on the disease. Even so, its selection as a re-
search target draws attention to the fact that SMRU has
not yet been able to move the focus of the majority of its
research to diseases of higher priority such as respiratory
infections, diarrheal diseases, or TB. These newer research
targets (non-malarial illnesses) comprise a minority of the
studies currently being performed by SMRU.
A need for research on vivax exists because, although
chloroquine treatment for vivax on the border is moder-
ately effective, there is anecdotal evidence that resistance
is emerging. This must be investigated. Given chloroquine
does not clear liver-stage parasites, there is a further need
to determine whether another existing treatment for vivax
(primaquine) can be optimized and made safe for use by
the border population. WHO and Thailand’s Ministry of
Public Health currently recommend primaquine as the
first-line treatment for vivax because it can clear liver-stage
parasites. Even so, this recommendation tends not to be
implemented by medical NGOs on the Thai-Myanmar
border. As confirmed by Investigator 05,
primaquine has been quite widely recommended, but I
can’t think of another drug where there’s a greater
disparity between the recommendation and the use…
And the reason for that is that primaquine is
potentially dangerous. People who have a geneticabnormality, glucose-6-phosphate-dehydrogenase
(G6PD) deficiency, it’s an X-linked genetic condition,
which is found very widely in areas where there is
malaria because it actually provides some protection
against malaria. Now if you give people with this
deficiency [primaquine], then they may hemolyze, so
their red blood cells would blow up and this can be
dangerous. So what we think happens is that doctors,
clinics, and so on in the public sector have the
recommendations but they also know the risks and
they think ‘well, as I cannot test for this condition’… so
they say ‘well, better be on the safe side, let’s not give it
[primaquine]’.
G6PD deficiency is thought to be widespread in Asian
populations. Along the Thai-Myanmar border, the NGOs
who take responsibility for health care provision do not
test for G6PD deficiency and, as a result, do not treat
cases of vivax with primaquine. Though there is no formal
evidence, the risks of deployment without routine G6PD
testing or adequate hospital support are considered to
outweigh the benefits.
Since primaquine isn’t routinely used, SMRU has not
been able to reduce the burden of vivax in the border
population. According to Investigator 01,
because we don’t use it [primaquine], it’s impossible to
control vivax… So now that falciparum has been
really suppressed, we started to think okay, let’s look
again at vivax and at this drug and whether we can
learn anything by utilizing new techniques and new
assays at our disposal and see whether we could make
it safer.
As such, the VHX trial is one of a series of studies being
conducted by SMRU to optimize the use of primaquine
for the border population.
Finally, for the selection of vivax to be consistent with
the ‘research for health justice’ framework, the intervention-
under-study must be appropriate (acceptable and imple-
mentable) for the host community. Primaquine is already
used in SMRU clinics, though not routinely, and has been
shown to be acceptable. Treatment with primaquine is
also likely to be implementable at SMRU clinics. The
series of studies on primaquine includes a comparative
evaluation of current rapid diagnostic tests for G6PD
deficiency. The intention is to do regular G6PD testing
at SMRU clinics after the most effective test is identified.
Facilitating factors
The VHX trial host community, disease target, and
intervention-under-study are largely consistent with
framework criteria. This is because of investigators’ com-
mitment to performing research addressing the border
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most optimal and appropriate strategies to prevent and
treat the main health problems of its research popula-
tion. This requires deep comprehension of the illnesses
that the border population experiences, which is why in-
vestigators have embedded SMRU in its host commu-
nity. According to a VHX trial investigator,
[t]hat distance from the lab to the field is all the
difference with SMRU. That we are in the field all the
time… You have to be in the middle with the
population. Work and most of your staff has to be
people from the population, so your technicians, your
computer staff, your nurses, they have to be from the
population where you work. That’s sort of, you know,
the close link is what makes it successful.
Most staff are recruited from the border population
and trained to do research and provide clinical care.
Staff not from the Thai-Myanmar border work alongside
local staff. Together they measure the health needs of
the population using epidemiological surveys, prospective
cohorts, and clinic data collection systems [18]. Collect-
ively, these methods give SMRU a strong understanding
of the health-related burden of disease experienced by its
research population.
Obstructive factors
Despite SMRU investigators’ commitment to improving
the border population’s health, the VHX trial focuses on
vivax rather than a more significant contributor to its
poor health status. Three factors explain why vivax and
primaquine were selected as the focus of the trial: SMRU
investigators’ commitment to performing studies of glo-
bal and local significance, the tendency of researchers to
specialize on specific diseases, and the research funding
environment. Each factor makes it extremely hard for a
long-term research collaboration to shift focus in ac-
cordance with a changing burden of illness in its host
community.
SMRU investigators are committed to conducting re-
search of direct benefit not only to the border popula-
tion but also to populations living in malaria-endemic
areas elsewhere [24]. When asked why the VHX trial fo-
cuses on vivax when the disease isn’t a large concern in
the community, Investigator 01 responded:
Well, because we have been working on malaria for
twenty years, so malaria is our main interest of
research. So we have accumulated the experience and
the know-how and the brain power with the scientists
to work on malaria, so I think… it makes sense to
because we are probably one of the few research
centers on malaria in the world that can do this kindof studies, so if we don’t do these studies, there are very
few other groups that do it. So I expect that the impact
on the [border] population’s overall health is going to
be small because the problem is not that big but when
you are going to utilize the finding elsewhere, then you
can multiply the impact. Like we did for the treatment
of falciparum malaria… For vivax, we could argue
that it’s not the top priority anymore in the population,
except that by studying vivax here we could demonstrate
that the parasite is becoming more resistant to the main
treatment, which is chloroquine, and, therefore, it’s even
more important to suppress it and control it because if
we don’t then the resistance is going to spread further.
Once the resistance has spread and increased, then the
impact on the population is very significant because you
have to change your treatment and your drugs.
Investigator 01 describes the potential for the VHX
trial to have local and global impact. Locally, the re-
search may lead to better treatment for a common dis-
ease in the face of emerging resistance. From a global
perspective, the research is important because, if chloro-
quine resistance has emerged, controlling vivax in the
border population is necessary to diminish the likelihood
of resistance spreading. Findings regarding the safe, ef-
fective use of primaquine can also be applied beyond the
Thai-Myanmar border to other Asian populations. This
will advance the goal of global malaria elimination.
Funding for the trial was sought from Wellcome Trust
as part of a larger Programme Grant on primaquine.
The Trust’s Programme Grant scheme (which no longer
exists) funded biomedical research into a series of re-
lated questions around a single topic (such as the use of
primaquine) for a duration of five years. The scheme did
not give strong consideration as to whether proposed
studies focused on local health concerns or would be
performed with worst-off communities. The four key cri-
teria upon which Programme Grant applications were
assessed were the science, the significance of the research
question, value for money, and investigators’ track re-
cords. Of these criteria, the first was the most critical. As
affirmed by Wellcome Trust representative 01,
the Programme Grant mainly is a scientific decision…
in terms of: is this good science, what is the research
question, why is the research question important, will
this project answer that research question, is the
project designed in an appropriate way, could it be
improved, does it need improvement and if it needs
improvement, that would generally suggest that this is
not a good proposal.
The global significance of research questions may have
been a factor when judging their importance and value
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if a proposal is
important to the local population and has
translatable outcomes that would be appropriate to
different populations in other areas, then obviously
that’s a higher priority than only has, you know, the
outcome is only applicable to a small group of people
in one region of the world… And things that have
translatable outcomes, so that larger numbers of
people, will have the bigger chance of success… The
more people it will help or improve the quality of life,
the better investment you’re making.
This suggests that research questions whose answers
are useful on a broad scale may be ranked higher, pro-
vided proposed studies have a solid scientific design and
investigators have a good track record. Local relevance is
not really a consideration beyond the fact that the
disease-under-study is prevalent in the host community.
Wellcome Trust’s position statement on research in-
volving people in developing countries does require the
conduct of research whose outputs can “become avail-
able to patients in those areas and be deliverable within
existing structures (or structures which are to be or
could readily be developed)” [25]. Nonetheless, the re-
view process for Programme Grant proposals did not ex-
plicitly reward proposals for testing “locally applicable”
interventions [25]. According to Trust representative 02,
considering whether outcomes of a study can be imple-
mented where the research will be conducted is “not the
main role of the funding committee”. He also notes it is
often beyond the scope of the funding committee to as-
sess projects’ chances of local applicability.
Wellcome Trust external reviewers and funding com-
mittees did not rely on criteria similar to those of the ‘re-
search for health justice’ framework to evaluate Programme
Grant applications. The Primaquine Programme Grant (of
which the VHX trial is part) was funded because it was
rated highly in terms of its science, research question, and
investigators’ track recordsn. That it promotes the health
of the worst-off reflects the commitment of investigators
rather than Wellcome Trust’s funding scheme.
Ultimately, SMRU investigators’ expertise in malaria
research and Wellcome Trust’s emphasis on track record
and value for money help explain why the VHX trial
does not focus on a higher priority illness in the border
population. Despite these obstacles to remaining respon-
sive to significant local health problems, SMRU is begin-
ning to broaden its research agenda, but Investigator 05
confirms that SMRU will keep a focus on malaria. He
states thatwe’re not going to move too much though. I think that,
you know, we’ll be building on strengths rather than
completely new areas. So I think it’s a reasonable
chance of success.
SMRU can only diversify so far and continue to be
successful in its grant applications and conduct of high-
quality research.
Fulfillment of obligations
Oxford University and VHX trial investigators’ selection
of a research target is generally consistent with frame-
work obligations, but Wellcome Trust falls short of its
obligation to fund ‘research for health justice’. Wellcome
Trust allocated US $65 million to research on neglected
diseases of the developing world in 2009 [26]. Here,
neglected diseases are defined as diseases that are “over-
whelmingly or exclusively incident in the developing
countries” and diseases that are “incident in both rich
and poor countries, but with a substantial proportion of
the cases in the poor countries” and where R&D is “not
in proportion to global need or addressed to the specific
disease conditions of poor countries” [27]. US $65 mil-
lion does not comprise even 10% of Wellcome Trust’s
annual £600 million (US $967 million) health research
expenditure, though this excludes funding for research
capacity strengthening in LMICs [28]. We suggest that
the Trust’s investment in research in LMICs could
increase.
Wellcome Trust’s funding could also be better targeted
to projects that are more consistent with framework re-
quirements. This will entail modifying existing grants
programs. In 2011, the Trust began awarding long-term
funding to individual researchers rather than to projects
and programs. Its New and Senior Investigator Awards
provide five to seven years of funding for investigators
whose research focuses on important scientific questions
[29]. To advance ‘research for health justice’, Wellcome
Trust might consider giving preference to applicants
whose clinical research
 tackles scientific questions relating to diseases
causing significant morbidity and mortality in LMIC
host communities,
 involves working with worst-off communities,
 builds long-term relationships with and the capacity
of LMIC researchers, and
 will generate outputs that can be used in host
communities.
Research capacity strengthening
For SMRU’s VHX trial to meet framework criteria for
research capacity strengthening, it should be conducted
as part of long-term partnerships with host country
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Thailand, and/or the border population. Such collabora-
tions should gradually build LMIC researchers and institu-
tions’ capacity to conduct clinical research independently.
As part of this process, the VHX trial ought to involve the
transfer of skills, knowledge, and resources to these re-
searchers [8].
Research capacity strengthening during the VHX trial
The VHX trial has strengthened the capacity of SMRU’s
Karen and Myanmar clinic and laboratory staff to collect
clinical research data on vivax [18]. All clinic staff in-
volved in the trial received training on malaria and trial
processes, including participant recruitment, case report
form completion, and study sample collection. Staff were
taught how to do malaria smears and hematocrits, which
were essential to identifying key trial endpoints. For
some clinic staff, this built research capacity, but for
others it did not because they had been involved in earl-
ier SMRU trials. Across the trial sites, research experi-
ence varied considerably prior to the trial commencing.
According to Investigator 03,
[i]n Mawker Thai, none of them had [research
experience]. Yeah, they’ve come a long way. They’ve
come a long way. In Wang Pha, they had quite a lot of
experience, so they were fine. In Mun Ru Chai, they’d
had some experience. Mae Kon Ken a lot of
experience. And Mae La, one medic has a lot of
experience. She’s actually since gone and the others
had little bit.
As most of SMRU’s malaria studies have been con-
ducted at Wang Pha Clinic, its staff are experienced in
data collection and patient care. For them, the VHX trial
meant learning to use new machines such as the G6PD
fluorescence machine rather than significantly enhancing
their research skills.
The VHX trial has built capacity amongst Mawker
Thai Clinic and Mae La Clinic medics, nurses, and home
visitors. An investigator affirmed that this is because
since I started the VHX, we’ve lost a number of senior
staff due to relocation, immigration, and then it’s
required that we ask a lot out of the more junior staff.
And I’m very pleased with the way some of them have
risen to the challenge and been able to take on take on
the leadership of the study.
Due to the resettlement of senior staff at Mawker Thai
and Mae La clinics, junior staff took on senior roles for
the VHX trial. The VHX trial has also built the research
capacity of SMRU laboratory staff to use new techniques
and conduct new assays.VHX trial training was conducted in two stages. First,
staff involved across all five trial sites were transported
to SMRU’s Mae Sot office for a training day. Two local
SMRU staff members were responsible for teaching staff
how to carry out the trial’s consent process. A VHX trial
investigator was responsible for explaining the purpose
of the trial and its methods, processes, and endpoints.
Second, the same investigator and two local staff mem-
bers went from site to site to practice the recruitment
process with the SMRU staff running the trial.
Alignment with ‘research for health justice’
The framework has five requirements for research cap-
acity strengthening at the project level. First, it calls for
ICR to strengthen clinical research capacity on health
conditions that are major contributors to poor health in
worst-off communities. Although vivax may not be the
top contributor to poor health on the Thai-Myanmar
border, it causes reasonably significant morbidity. Sec-
ond, ICR should strengthen clinical research capacity on
conditions where such research is needed. As noted, a
need for research on vivax exists because resistance to
chloroquine may be emerging and treatment for vivax
has yet to be optimized for the border population.
Third, ‘research for health justice’ demands that when
high-income country researchers and institutions per-
form ICR in LMICs, it be conducted through partner-
ships with LMIC researchers and institutions. The VHX
trial is conducted through the Mahidol-Oxford Tropical
Medicine Research Unit, established in 1979. SMRU was
created as a field unit of that collaboration. The trial is
led by Oxford University investigators, with assistance
from American and Myanmar investigators. No investi-
gators are from the border population or Thailand. VHX
trial investigators are, however, working with members
of the border population to conduct the study. Although
physicians from Myanmar and high-income countries fill
more senior SMRU positions, individuals from the border
population serve as clinic, laboratory, and research staff.
The combination of Myanmar investigators and local re-
search staff is the closest achievable approximation of a re-
search group from the border population. While external
investigators did not collaborate with Thai researchers,
their partnering practice (with the border population
and Myanmar doctors) is consistent with ‘research for
health justice’.
Fourth, the framework requires that ICR partnerships
be of lengthy duration so that they build the capacity of
local partners to perform clinical research. The VHX
trial is being conducted as part of a 25 year partnership
between, at the institutional level, Mahidol and Oxford
universities and, at the individual level, Oxford University
researchers and members of the border population. Insti-
tutional capacity has been built at the Mahidol-Oxford
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ministration, ethics review, data monitoring, and logistics.
The Clinical Trial Support Group is now responsible for
these tasks. Its staff are mostly Thai, though its head is
Malaysian. SMRU’s research capacity-building is mainly
directed towards the border population and doctors from
Myanmar and Western countries. The VHX trial, for ex-
ample, supports the PhD training of an American doctor.
However, ‘research for health justice’ emphasizes building
the capacity of Myanmar and Thai physicians, wher-
ever possible, rather than physicians from high-income
countries.
SMRU has not built the border population’s independ-
ent clinical research capacity. After 25 years, researchers
from Oxford University remain in-charge of SMRU and
are responsible for making major research decisions.
These investigators identified the research questions to
be investigated as part of the Primaquine Programme
Grant, chose to apply to Wellcome Trust for funding,
set the VHX trial objectives, and determined how the
trial was designed. The two Myanmar doctors who
served as co-investigators on the VHX trial were not in-
volved in these processes. Local staff are responsible for
participant recruitment and data collection. Data ana-
lysis will also be done primarily by local staff from
SMRU’s data management center, but the plan for data
analysis will be designed by external investigators and
the Mahidol-Oxford Tropical Medicine Research Unit’s
statistician. VHX trial publications will be written primar-
ily by investigators from Europe and the United States.
Finally, the framework calls for investigators to build
research capacity at the individual level (i.e., of persons
from Myanmar, Thailand, or the border population) dur-
ing the VHX trial. Trial investigators have strengthened
the capacity of SMRU staff from the border population
to manage the day-to-day running of clinical research.
This involved skill-building in participant recruitment,
data collection, and leadership.Facilitating and obstructive factors
Successful research capacity strengthening at the individ-
ual level has been achieved due to Wellcome Trust fund-
ing practices and SMRU being embedded in its host
community. Wellcome Trust representatives affirm that
research capacity strengthening is one of the Trust’s “major
missions”. Where research is undertaken in LMICs, the
Trust “expects some capacity-building—training of local
staff, encouragement of local staff to take part in the re-
search, train them in PhDs, if possible” and “advocates
that things are done as locally as possible to build cap-
acity”. Accordingly, there was an allocation in the VHX
trial budget for training and capacity-building related to
the trial. As confirmed by Investigator 05,there wasn’t a specific budget that was set aside for
teaching that was not germane to the trial. There was
certainly a budget for developing the trials, training
people about the trial, you know, doing the G6PD testing,
all that stuff… so it’s related to the trial in this budget.
Training provided by investigators then focused solely
on the VHX trial and was directed almost exclusively to
members of the border population. This is consistent
with ‘research for health justice’ requirements at the pro-
ject level.
Funding arrangements with Wellcome Trust have also
made possible the long-term partnerships between Oxford
and Mahidol universities and between SMRU investigators
and the border population. The Mahidol-Oxford Tropical
Medicine Research Unit and SMRU are part of Wellcome
Trust’s Major Overseas Programme in Thailand, which
has been funded since 1979, with the Trust providing fi-
nancial resources to create facilities and infrastructure for
research and to support fellowships, project grants, and
program grants. Some of this funding can be used for re-
search capacity strengthening.
SMRU’s practice falls short of ‘research for health just-
ice’ with respect to building the ability of Karen and
Myanmar individuals to perform clinical research inde-
pendently. (Please note, this comment relates to the out-
come of SMRU’s 25-year collaboration not the VHX
trial, as single trials are not expected to develop such a
high level of research capacity.) After 25 years, members
of the border population are not involved in designing
trials or applying for funding. Investigator 01 elaborates
on why this is and why it is unlikely that local staff will
ever run SMRU:
I thought many years ago that it could be, but I have
sort of given up the idea of building a 100% bridge
Karen research organization. It’s not going to happen.
And the reasons that I could identify are that they
don’t have the skills. I mean, not the skills, I’m not
talking about the technical skills, but they don’t have
the educational background and so even if you tried to
you know train and give training, they are lacking all
the basics and so you have to start from zero… Plus, it
has happened over the 20 years we had some people
who were academically bright or some students in
Myanmar who came over here and they could have
developed their own research ideas, but they went or
are resettled in America, in Australia, and so this
turnover means that we can’t keep people long enough
to develop their skills up to a level where they become,
except maybe the team that does data entry, the data
management people, they now are quite independent
and can develop their own databases, their own
algorithms for cleaning up the database.
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particularly for the Karen. They face considerable perse-
cution from the military and are repeatedly forced to flee
their homes and resettle within Myanmar. This is not
conducive to gaining an education. Irrespective of their
lack of education, some clinic staff could one day as-
sume a leadership role at SMRU. However, the resettle-
ment process for stateless persons and the mobility of
the border population mean that such individuals do not
remain at SMRU for long. Even lower level research
roles must be re-assigned regularly due to resettlement
and migration. It, therefore, may not be reasonable to
expect research capacity to be built to a level of independ-
ent proficiency when working with stateless populations
who lack access to secondary and tertiary education
opportunities.
In recent years, SMRU has recruited six Myanmar
physicians, two of whom are doing a PhD. In other
SMRU trials, these doctors have assumed the role of in-
vestigator primarily responsible for trial management.
As a longstanding collaboration, this commitment to
training investigators from Myanmar is integral to ‘re-
search for health justice’. However, the VHX trial is sup-
porting the PhD training of an American doctor rather
than an individual from Thailand or Myanmar. The fact
that PhD students are not drawn from the border popu-
lation is unsurprising for the aforementioned reasons.
According to Investigator 01, SMRU does not train Thai
doctors because they are not interested in its research.
Thai doctors are not willing to come and work in Mae
Sot because it is viewed as too remote and dangerous.
Historically, there is animosity between the Thai and
Myanmar populations. SMRU trains more Western doc-
tors for PhDs than Myanmar doctors because there are
few candidates from Myanmar. In part, this reflects the
lack of educational opportunities and the fact that the
job involves working in a conflict zone that is particu-
larly dangerous for the Karen and others from Myanmar.
These factors stymie external investigators’ efforts to de-
velop local investigators’ (from Myanmar) capacity to
take over SMRU’s leadership.
Fulfillment of obligations
Through its Major Overseas Programme in Thailand,
Wellcome Trust upholds its obligation to create funding
schemes that support long-term research collaborations
between high-income country and LMIC institutions.
The scheme is partly responsible for financing a collab-
oration between Oxford researchers and research staff
from the border population.
Oxford University behaved consistently with framework
requirements by establishing a long-term collaboration
with Mahidol University and strengthening its capacity
to administer grants and coordinate ethics approvals forclinical trials. Oxford researchers uphold their obliga-
tion to set up collaborations with researchers from
LMICs by performing trials with doctors from Myanmar
and staff from the border population. As part of the
VHX trial, they have built the research capacity of indi-
viduals from the border population, which is consistent
with framework demands. Over the years, for reasons
that are understandable, external investigators have not
built their local counterparts' capacity to conduct clin-
ical research independently.
Post-trial commitments
This section assesses the likelihood that vivax malaria
treatment practice will change in the host community
post-trial. The framework requires these changes be fi-
nanced by a global health institution and be delivered to
trial participants and their communities though the Thai
health system.
Likely changes to treatment practice associated with VHX
trial
Depending on the VHX trial results, investigators affirm
that any one of three post-trial scenarios is possible, with
the first two being most likely:
1. The VHX trial confirms that chloroquine resistance
on the border has reached unacceptable levels. It
also shows that primaquine is the most effective
treatment for vivax. The local treatment is changed
to primaquine directly after the VHX trial. This
primaquine regimen is later amended based on the
results of the next trial funded under the
Primaquine Programme Grant, which tests different
primaquine regimens.
2. The VHX trial shows that chloroquine resistance on
the border has not risen to unacceptable levels. It
also shows that primaquine is the most effective
treatment for vivax. The local treatment for vivax is
not changed until after the trial testing different
primaquine regimens is completed.
3. The VHX trial shows that chloroquine resistance on
the border has not risen to unacceptable levels. It
also shows that chloroquine is the most effective
treatment for vivax. There is no change in the
treatment for vivax.
If the second scenario eventuates, the significance of
the VHX trial will be scientific, as it will have improved
the design of the subsequent primaquine regimen study.
Data from the VHX trial suggests that artesunate is inef-
fective in treating vivax relative to chloroquine and prima-
quine because patients treated with it relapse more
frequently. As a result, the primaquine regimen study will
evaluate seven and fourteen-day regimens of primaquine
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ginally intended.
The high likelihood that SMRU will change the treat-
ment regimen for vivax in its clinics after the VHX trial
is reiterated by T-CAB members. When asked to com-
ment on the benefits of SMRU research, they noted that
the medicines tested by SMRU will assist and treat “fu-
ture people” and “future generations” of their communi-
ties. T-CAB member 02 was asked “so, regarding that
research on this mosquito virus, what does the research
benefit for this clinic?” In response, he states: “this new
medicine is for this clinic in upcoming one day. If the
old medicine is not effective any more, then this new
medicine benefits for this clinic”. Where drug resistance
develops, SMRU clinics can make available treatments
proven efficacious by its research. T-CAB members
recognize that once SMRU research indicates that new
treatments are more effective than those currently in use
in its clinics, SMRU doctors and medics will prescribe
the new medicines.
Ultimately, our data suggest that changes to treatment
practice in the VHX trial host community will take place
if needed. However, if high levels of chloroquine resist-
ance are not evidenced by the VHX trial, the obligation
will only be fulfilled after the primaquine regimen study
is completed.
Implementing changes in local treatment practice
Since SMRU runs clinics on the border, translating new
evidence into local treatment practice is straightforward.
As affirmed by Investigator 01, “because we work with
the population and in the population, from tomorrow,
we decide to change the treatment, we do it”. When re-
searchers are confident in trial findings, changes are im-
plemented in clinical practice. To do so, the Malaria
Handout (i.e., treatment guidelines for malaria written by
SMRU) is revised [18]. The process begins with a meeting
of SMRU doctors to discuss
what the changes are, why we have to change, what
the evidence is, and we discuss the practicalities, we
discuss the cost, we discuss you know all the
implications, then we change our guideline and then
we have a phase where we train the staff to adapt to
the changes and then they start implementing the
changes in the clinics.
Once changes to the Malaria Handout have been dis-
cussed, different doctors are given sections of the docu-
ment to revise. For the next round of revisions, the vivax
portion will probably be allocated to the American in-
vestigator in charge of managing the VHX trial. Revi-
sions to the Malaria Handout on the treatment regimen
for vivax will be based on the results of the VHX trialand subsequent primaquine regimen study. These changes
will be finalized by the head of SMRU, Francois Nosten.
The doctor-in-charge at each SMRU clinic will be respon-
sible for educating staff on the new treatment practice.
These clinics are utilized by trial participants and their
communities.
After SMRU revises the Malaria Handout, it is shared with
the five medical NGOs operating on the Thai-Myanmar
border. It, thus, affects treatment practice in clinics utilized
by the wider border population. To inform the NGOs about
the new treatment guidelines, SMRU hosts an annual work-
shop where SMRU doctors distribute the revised Malaria
Handout and give training on the implementation of new
procedures [18]. Whether the NGOs decide to change
their policy is up to them, but SMRU’s track record and
the strength of evidence it provides means that the NGOs
usually adopt the Malaria Handout as their treatment
guidelines.
By changing the treatment regimen for vivax in SMRU
clinics, investigators will uphold the obligation to change
treatment practice in the VHX trial host community.
This goes beyond what is expected by ‘research for
health justice’. The framework does not oblige external
trial investigators to provide post-trial benefits because
it falls outside the scope of their typical role. It recom-
mends post-trial changes to treatment practice be coor-
dinated by a global health institution and implemented
through local health systems or through medical NGOs
affiliated with them. Researchers are only responsible for
identifying and supporting a local health structure(s) to
apply for funding from a global health institution. The
Thai health system has not taken responsibility for pro-
viding health care to the border population (aside from
legal migrants who can afford health insurance) and is
largely inaccessible to them. Although SMRU investigators
will deviate from framework requirements by implement-
ing changes in treatment practice through a non-state sys-
tem, they cannot be held responsible for decisions of the
Thai government. They deserve praise for meeting the re-
sponsibilities of others.Facilitating factors
The factors facilitating implementation of changes to local
treatment practice for vivax include SMRU’s dual role as a
research unit and health care provider; the existence of
the Global Fund to Fight AIDS, Tuberculosis, and Malaria;
primaquine being off-patent; and SMRU clinics’ position
outside the Thai health system. By assuming a dual respon-
sibility, SMRU enables the efficient and effective translation
of its research results into practice in clinics used by its
research population [18]. SMRU will be able to forecast
how much primaquine it needs, procure it, and deliver
it to patients from the border population.
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be financed by the Global Fund, a global health partner-
ship that supports scaling-up access to proven interven-
tions for HIV/AIDS, TB, and malaria. As it is a health care
provider, SMRU can obtain funding through the Global
Fund and is not solely reliant on research funders. (Most
research funders, including Wellcome Trust, do not grant
funding for post-trial activities.) Primaquine is an older
drug, so it is off-patent and inexpensive. Numerous manu-
facturers exist and, with Global Fund assistance, cost will
not prevent SMRU from buying enough primaquine to
meet the border population’s need. Primaquine will be
free-of-charge at SMRU clinics, ensuring affordability at
the patient-level.
SMRU can change treatment practice in its clinics as
it chooses. It does not have to follow Thai treatment
policy because it does not treat Thai people. Availability,
affordability, and adoption of the new primaquine regi-
men in the host population can, thus, each be achieved.
Obstructive factors
Thailand’s unwillingness to fully open its health system
to stateless populations would, in most cases, be a sig-
nificant obstacle to external actors upholding their post-
trial benefit obligations. SMRU has overcome this by
establishing a health care system for the border population
that supplements the Thai system. Although ‘research for
health justice’ does not oblige external research actors to
improve health care systems in host communities of ICR,
assuming a dual role as research unit and health care
provider is a pragmatic response in the context of work-
ing with stateless populations for whom Thailand and
Myanmar are unwilling to uphold their obligations.
Nevertheless, since SMRU clinics are not part of a state-
run health system, this strategy raises the issue of long-
term sustainability of treatment access. For example, a
problem may be caused by the eventual retirement of
SMRU head, Francois Nosten.
Fulfillment of obligations
SMRU investigators are high likely to change treatment
practice for vivax on the border after the primaquine
regimen study is completed. The Global Fund will finance
the provision of the new primaquine regimen to the host
community.
Conclusions
This paper provides further evidence of how empirical
research can be employed as a useful supplement to
conceptual research. Our study of the VHX trial revealed
shortcomings of the ‘research for health justice’ frame-
work and identified limits to what it may be reasonable
for the framework to require in the context of research
with stateless populations.The SMRU research model is worthy of replication.
The VHX trial is only minimally inconsistent with ‘re-
search for health justice’ requirements in three areas,
which, given that this was a retrospective analysis of a
new ethical standard, is quite remarkable. The selection
of vivax as the health condition-under-study indicates
that it may not be possible for long-term collaborations
to alter their research agendas to align with changes in
the burden of disease in their research populations in
the short to medium term. Instead, they may have to
make the transition much more gradually due to the
disease-specific nature of research expertise and the re-
search funding environment.
After 25 years of collaboration, the border population’s
research training does not cover the capacities necessary
for conducting research independently. Karen and Myanmar
refugees, migrants, and displaced persons are quite mo-
bile, creating regular staff turnover, and lack access to a
secondary and tertiary education system, making it
largely impossible to train them to become investiga-
tors. This suggests that the framework may require too
much of long-term collaborations in terms of research
capacity strengthening for stateless populations. It also
highlights the fact that capacity-building obligations
need clear boundaries in the same way as obligations to
provide ancillary care and treatment post-trial. The con-
tent and extent of capacity-building obligations need to
be clarified (i.e. how much and what sort of capacity-
building is required in different contexts and for differ-
ent sorts of people).
Post-trial benefits will not be provided through a state-
run health care system after the VHX trial. The case study
highlights the reality that many LMICs do not make
health care accessible to refugee and migrant populations
within their borders. The VHX trial demonstrates that
framework requirements are achievable rather than un-
realistic and aspirational in such contexts. It shows that
researchers can uphold obligations linking ICR to justice
in global health, despite two LMICs failing to fulfill their
duty of care to the border population, and describes their
successful strategy for doing so. By embedding their in-
stitution in its host community, obtaining money from a
funder committed to long-term research capacity strength-
ening, and securing financing for post-trial provision of
medicines from the Global Fund, SMRU investigators
have been able to adhere to ‘research for health justice’
and will make benefits available to the host community
post-trial.
While this case study shows that external research ac-
tors from high-income countries can uphold ethical obli-
gations linking ICR to justice in global health and offers
an initial description of how they might do so, other suc-
cessful strategies still need to be identified, as LMIC set-
tings differ considerably. The context of the VHX trial is
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populations who cannot access state health systems. More
frequently, ICR is performed with populations that are
citizens of specific states and in settings where state health
systems are accessible but under-resourced and offer
limited care. Additional empirical research is needed to
determine what approaches are relied on in these settings
to link trials to justice in global health.Endnotes
aAll references to the worst-off refer to those who are
worst-off in terms of their health.
bThe 2013 Declaration of Helsinki gives the primary
obligation for the provision of post-trial benefits to re-
searchers, sponsors, and host country governments in
Paragraph 34. The 2002 CIOMS guidelines state that
“the sponsor and the investigator must make every ef-
fort to ensure that any intervention or product devel-
oped, or knowledge generated, will be made reasonably
available” in Guideline 10. Although other actors are
mentioned in the commentary to Guideline 10, they are
only tasked with being part of discussions and negotia-
tions regarding making successful interventions available
and distributed post-trial, rather than being assigned the
responsibility of making them available.
cPlease note that this paper is the latest paper in a
series of conceptual and empirical papers on linking
international clinical research to global justice. The other
papers in the series are (in the order that they should be
read): 1) Pratt et al. [14]. “Evaluating the capacity of theor-
ies of justice to serve as a justice framework for inter-
national clinical research.” American Journal of Bioethics
12(11):30-41; 2) Pratt, B. & Loff, B. [10]. “A framework to
link international clinical research to the promotion of
justice in global health.” Bioethics, doi: 10.1111/bioe.12009;
3) Pratt et al. [30]. “Ancillary care: Theory and practice in
international clinical research.” Public Health Ethics, doi:
10.1093/phe/pht015; and 4) Pratt et al. [18]. “Closing the
translation gap for justice requirements in international re-
search.” Journal of Medical Ethics. doi:10.1136/medethics-
2011-100301.
dThe VHX trial was not designed to meet framework
requirements.
eWe do not know the legal status of all members of
the border population with whom SMRU works. It likely
varies from person to person. Although all Karen and
Myanmar refugees, migrants, and displaced persons may
not be owed formal legal obligations by Thailand, we
take the position that Thailand has a moral obligation to
provide health care to the border population.
fSee Pratt, B., Lwin, K.M., Zion, D., Nosten, F., Loff. B, &
Cheah, P.Y. (2013). “Exploitation and community engage-
ment: Can CABs successfully assume a role minimisingexploitation in international research?” Developing World
Bioethics, doi:10.1111/dewb.12031.
gThe aim of capacity-building under the framework is
to support the stateless population without assisting or
enabling the unjust government that it has fled.
hRegistered economic migrants can access Thai health
insurance for 1,300 baht per year. This insurance does
not cover some conditions, including difficulties during
pregnancy, dialysis, and antiretroviral treatment beyond
that required to prevent mother-to-child transmission of
HIV. Those refugees, illegal migrants, or displaced persons
who manage to surmount significant physical and military
barriers to reach Thai hospitals will also be treated. Get-
ting to Thai hospitals requires overcoming obstacles such
as leaving Mae La refugee camp, traveling twenty kilo-
metres (or more) beyond the border into Thailand, and/or
passing through military checkpoints intended to prevent
refugees and illegal migrants from crossing into Thailand.
Such barriers are not frequently overcome, but whenever
a non-Thai patient, whether legally in Thailand or not,
manages to present him/herself to the public hospitals, s/
he is provided with care. If the patient is too poor to pay,
this care is free.
iLife expectancy in Myanmar is 65 years [23].
jA country with an infant mortality rate of 50 per
1,000 live births would fall 175th out of the 222 countries
listed in the CIA World Factbook.
kA country with a maternal mortality rate of 252 per
100,000 live births would fall 139th out of the 183 coun-
tries listed in the CIA World Factbook.
lThe burden of falciparum malaria has fallen dramatic-
ally (99% in twenty years) in refugee camps and in villages
in the border districts as a result of a control strategy
designed by SMRU and implemented by all medical
NGOs in the area.
mIn 1985, malaria was the first cause of morbidity and
mortality, accounting for 16% of deaths and 40% of MSF
clinic consultations.
nWellcome Trust representatives confirm the Prima-
quine Programme Grant application was successful be-
cause scientifically it was “a strong study in itself” and
asked a compelling research question. SMRU investigators
have a strong track record in the field of malaria research.
External reviewers noted that the applicants were leaders
in the field and uniquely positioned to carry out the
studies.Additional files
Additional file 1: Main requirements of the ‘research for health
justice’ framework for international clinical trials. The table identifies
the criteria that single international clinical trials must meet in three areas
(selecting a research target, research capacity strengthening, and post-trial
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framework.
Additional file 2: Obligations under the ‘research for health justice’
framework. The table identifies the obligations of justice of various types
of external research actors in relation to three aspects of international
clinical research (selecting a research target, research capacity
strengthening, and post-trial benefits).
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